| Name | Title | Contact Details |
|---|
Omnichem USA is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Applied Biophysics Inc is a Troy, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Our mission is clear: To build a breakthrough oncology company creating neoantigen-based therapeutics that significantly improve the lives of patients. Neon Therapeutics is a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. By directing the immune system towards these targets, we believe our neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy that will drive a strong risk-benefit profile to dramatically improve patient outcomes. We pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies. Our platform seeks to identify and harness the most therapeutically relevant neoantigens present within each patient`s tumor, and comprises three key elements that form an iterative feedback loop: our RECONTMBioinformatics Engine; our deep capabilities in peptide chemistry and manufacturing; and our combined NEON-STIMTM T cell biology and immune-monitoring expertise. Our company builds on more than a decade of pioneering work by our world-class scientific founders across multiple leading global institutions including the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, MD Anderson Cancer Center, the Netherlands Cancer Institute and Washington University in St. Louis. Our founders were central to the development of both the fields of immuno-oncology and neoantigens and have published a number of seminal papers outlining the importance of neoantigens as critical immune targets for treating cancer.
Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology. Exoneural biology is broadly implicated in human health and disease. Fueled by our dynamic Exoneural Medicine Platform™, we are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.